Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:34 pm Sale | 2024-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 0 0.000% | -703,868 (Position Closed) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 1,181,144 8.500% | -23 (-0.00%) | Filing History |
| 2024-02-02 09:42 am Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 703,868 5.000% | -187,000 (-20.99%) | Filing History |
| 2023-11-13 4:41 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 1,181,167 8.500% | 1,181,167 (New Position) | Filing History |
| 2023-11-13 4:10 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | EVENTIDE ASSET MANAGEMENT LLC | 1,394,336 9.990% | 1,394,336 (New Position) | Filing History |
| 2023-11-13 4:03 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management LP | 1,394,336 9.990% | 1,394,336 (New Position) | Filing History |
| 2023-11-13 08:24 am Purchase | 2023-11-01 | 13D | VYNE Therapeutics Inc. VYNE | AI Biotechnology LLC | 3,201,980 19.990% | 3,201,980 (New Position) | Filing History |
| 2023-11-02 4:15 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 890,868 6.400% | 890,868 (New Position) | Filing History |
| 2022-02-14 7:33 pm Sale | 2021-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Perceptive Advisors LLC | 134,756 4.500% | -142,349 (-51.37%) | Filing History |
| 2021-08-25 5:04 pm Purchase | 2021-08-17 | 13G | VYNE Therapeutics Inc. VYNE | Perceptive Advisors LLC | 277,105 9.600% | 277,105 (New Position) | Filing History |
| 2021-07-09 6:05 pm Purchase | 2021-06-30 | 13G | VYNE Therapeutics Inc. VYNE | BlackRock Inc. BLK | 57,649 2.000% | 57,649 (New Position) | Filing History |
| 2021-02-16 4:13 pm Unchanged | 2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE | GREAT POINT PARTNERS LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2021-02-16 3:39 pm Purchase | 2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Perceptive Advisors LLC | 1,505,323 14.300% | 1,505,323 (New Position) | Filing History |
| 2021-02-16 3:28 pm Purchase | 2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Point72 Asset Management, L.P. | 1,447 0.100% | 1,447 (New Position) | Filing History |
| 2021-02-16 2:41 pm Sale | 2020-12-31 | 13G | MENLO THERAPEUTICS INC MNLO | FIRST MANHATTAN CO. LLC. | 21,319 0.010% | -2,146,694 (-99.02%) | Filing History |
| 2021-02-11 1:56 pm Sale | 2020-12-31 | 13G | MENLO THERAPEUTICS INC MNLO | JANUS HENDERSON GROUP PLC JHG | 0 0.000% | -1,281,133 (Position Closed) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | VYNE Therapeutics Inc. VYNE | BlackRock Inc. BLK | 166,511 7.100% | 166,511 (New Position) | Filing History |
| 2020-06-11 5:10 pm Purchase | 2020-03-09 | 13G | MENLO THERAPEUTICS INC MNLO | Perceptive Advisors LLC | 22,876,410 14.000% | 22,876,410 (New Position) | Filing History |
| 2020-06-11 5:09 pm Sale | 2020-06-09 | 13G | MENLO THERAPEUTICS INC MNLO | Vivo Capital VIII LLC | 3,643,824 2.200% | -367,412 (-9.16%) | Filing History |
| 2020-04-16 12:47 pm Sale | 2020-04-07 | 13D | MENLO THERAPEUTICS INC MNLO | venBio Global Strategic Fund II L.P. | 0 0.000% | -1,461,552 (Position Closed) | Filing History |